Viral and Non-Viral Nanoplasmid Vectors with Improved Production
Summary
USPTO granted patent US12600984B2 to Aldevron, L.L.C. covering methods for improving replication of covalently closed circular plasmids through replacement of Pol I-dependent origins with Pol III-dependent origins. The patent also claims antibiotic marker free covalently closed circular recombinant DNA molecules. The patent contains 31 claims.
What changed
USPTO issued patent grant US12600984B2 to Aldevron, L.L.C. for methods of improving replication of covalently closed circular plasmids by replacing Pol I-dependent origins of replication with Pol III-dependent origins. The patent also claims antibiotic marker free recombinant DNA molecules and covers structured DNA sequences including inverted repeat sequences, direct repeat sequences, homopolymeric repeat sequences, eukaryotic origins of replication, and eukaryotic promoter enhancer sequences.
Affected parties in the biotechnology and pharmaceutical manufacturing sectors should consider this patent when developing plasmid-based vector products. The patent may affect freedom-to-operate for competitors developing similar nanoplasmid production methods. No compliance deadlines or penalties apply to this IP grant.
What to do next
- Monitor for potential licensing opportunities
- Review patent claims for freedom-to-operate analysis
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Viral and non-viral nanoplasmid vectors with improved production
Grant US12600984B2 Kind: B2 Apr 14, 2026
Assignee
Aldevron, L.L.C.
Inventors
James A. Williams
Abstract
A method for improving the replication of a covalently closed circular plasmid is provided. The method includes providing a covalently closed circular plasmid having a Pol I-dependent origin of replication, and an insert including a structured DNA sequence selected from inverted repeat sequences, direct repeat sequences, homopolymeric repeat sequences, eukaryotic origins of replication or eukaryotic promoter enhancer sequences, wherein the structured DNA sequence is located at a distance of less than 1000 bp from the Pol I-dependent origin of replication in the direction of replication. The method also includes modifying the covalently closed circular recombinant molecule such that the Pol I-dependent origin of replication is replaced with a Pol III-dependent origin of replication, whereby the resultant Pol III-dependent origin of replication covalently closed circular plasmid has improved replication. An antibiotic marker free covalently closed circular recombinant DNA molecule is also provided.
CPC Classifications
C12N 15/85 C12N 15/70 C12N 15/86 C12N 2740/15043 C12N 2740/15052 C12N 2750/14143 C12N 2750/14152 C12N 2800/90 C12N 2820/55 C12N 2800/101 C12N 2800/24
Filing Date
2020-09-18
Application No.
17026101
Claims
31
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.